Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 5.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 477,751 shares of the specialty pharmaceutical company’s stock after purchasing an additional 24,481 shares during the quarter. Bank of New York Mellon Corp owned 0.79% of Jazz Pharmaceuticals worth $58,835,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth $25,000. UMB Bank n.a. boosted its position in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares in the last quarter. Itau Unibanco Holding S.A. boosted its position in shares of Jazz Pharmaceuticals by 63.2% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after acquiring an additional 172 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Jazz Pharmaceuticals by 49.8% during the 4th quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock worth $76,000 after acquiring an additional 206 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its position in shares of Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 704 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Needham & Company LLC upped their price objective on Jazz Pharmaceuticals from $205.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and set a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $182.47.

Jazz Pharmaceuticals Stock Down 0.9 %

JAZZ opened at $138.95 on Wednesday. The business has a 50 day moving average price of $127.31 and a two-hundred day moving average price of $119.57. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a market cap of $8.44 billion, a PE ratio of 19.57, a P/E/G ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. The trade was a 10.24 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,113 shares of company stock worth $2,551,834. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.